Skip to Content

Synagis (palivizumab) Disease Interactions

There is 1 disease interaction with Synagis (palivizumab):

Major

Palivizumab (applies to Synagis) platelet disorders

Major Potential Hazard, High plausibility. Applicable conditions: Coagulation Defect, Thrombocytopathy, Thrombocytopenia

Palivizumab is administered by IM injection and the risk of bleeding is increased in the presence of platelet function disorders and/or thrombocytopenia. Therapy with palivizumab should be administered cautiously in patients with coagulation disorders or thrombocytopenia.

References

  1. "Product Information. Synagis (palivizumab)." Ross Product Division Pharmaceuticals, Columbus, OH.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.